{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:21:05Z","timestamp":1740122465522,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["British Heart Foundation"],"award-info":[{"award-number":["British Heart Foundation"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-02948-5","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T13:03:17Z","timestamp":1708002197000},"page":"739-741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor\u2013related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate"],"prefix":"10.1007","volume":"57","author":[{"given":"Richard J","family":"Buka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip LR","family":"Nicolson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"issue":"1","key":"2948_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11239-023-02820-y","volume":"56","author":"SS Sutton","year":"2023","unstructured":"Sutton SS, Magagnoli J, Cummings TH, Dettling T, Lovelace B, Christoph MJ et al (2023) Real-world clinical outcomes among US veterans with oral factor xa inhibitor\u2013related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. J Thromb Thrombolysis 56(1):137\u2013146","journal-title":"J Thromb Thrombolysis"},{"issue":"16","key":"2948_CR2","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","volume":"329","author":"SV Wang","year":"2023","unstructured":"Wang SV, Schneeweiss S, Franklin JM, Desai RJ, Feldman W, Garry EM et al (2023) Emulation of Randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA 329(16):1376\u20131385","journal-title":"JAMA"},{"key":"2948_CR3","doi-asserted-by":"crossref","unstructured":"Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JPA (2016) Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: Meta-epidemiological survey. BMJ (Online). ;352","DOI":"10.1136\/bmj.i493"},{"key":"2948_CR4","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/eurheartj\/ehs114","volume":"33","author":"IJ Dahabreh","year":"2012","unstructured":"Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H et al (2012) Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J 33:1893\u20131901","journal-title":"Eur Heart J"},{"key":"2948_CR5","doi-asserted-by":"crossref","unstructured":"Ren J, Cislo P, Cappelleri JC, Hlavacek P, DiBonaventura M (2023) Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study. BMC Med Res Methodol. 23(1)","DOI":"10.1186\/s12874-023-01835-6"},{"issue":"2","key":"2948_CR6","first-page":"1","volume":"3","author":"AT Cohen","year":"2022","unstructured":"Cohen AT, Lewis M, Connor A, Connolly SJ, Yue P, Curnutte J et al (2022) Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life\u2010threatening direct oral anticoagulant\u2010related bleeding. J Am Coll Emerg Physicians Open 3(2):1\u201310","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"2948_CR7","doi-asserted-by":"crossref","unstructured":"Costa OS, Connolly SJ, Sharma M, Beyer-Westendorf J, Christoph MJ, Lovelace B et al (2022) Andexanfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care. 26(1)","DOI":"10.1186\/s13054-022-04043-8"},{"key":"2948_CR8","doi-asserted-by":"crossref","unstructured":"Keinath JJ, Lekura J, Hauser CD, Bajwa MK, Bloome ME, Kalus JS et al (2023) Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor xa inhibitor associated bleeds. J Thromb Thrombolysis.","DOI":"10.1007\/s11239-023-02840-8"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02948-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02948-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02948-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:07:40Z","timestamp":1713442060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02948-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":8,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2948"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02948-5","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"assertion":[{"value":"4 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required or sought.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"RJB has received honoraria from Bayer, Sobi, and Sanofi, and Takeda.DJS has received honoraria from Pfizer-BMS and Bayer.PLRN has received research grants from Novartis, Principia, Sanofi, and Rigel Pharmaceuticals and has received had honoraria from Bayer, Grifols and Takeda.RJB and PLRN have received an externally-sponsored research grant from AstraZeneca to audit the use of reversal agents for direct oral anticoagulant-associated bleeding across the UK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosures"}}]}}